Идринол®

General characteristics. Structure:

Active agent: a meldoniya a dihydrate without the adsorbed moisture – 100 mg (in terms of meldony anhydrous – 80,21 mg);
excipients: water for injections.

Pharmacological properties:

Pharmacodynamics. Meldony – a structural analog of a gamma butyrobetaine – substance which is present at each cell of a human body. Meldony suppresses gamma бутиробетаингидроксигеназу, reduces synthesis of a carnitine and transport of long-chain fatty acids through covers of cells, interferes with accumulation in cells of the activated forms of unoxidized fatty acids - a derivative atsilkarnitsin and acylcoenzyme A. In the conditions of ischemia recovers balance of processes of delivery of oxygen and its consumption in cells, prevents disturbance of transport of adenosine triphosphoric acid (ATP). Along with it activates glycolysis which proceeds without additional consumption of oxygen. As a result of decrease in concentration of a carnitine the gamma butyrobetaine having vazodilatiruyushchy properties is strenuously synthesized.

The mechanism of action defines variety of its pharmacological effects: increase in working capacity, reduction of symptoms of an intellectual and physical overstrain, activation of fabric and humoral immunity, cardiotyre-tread action. In case of acute ischemic injury of a myocardium slows down formation of a zone of a necrosis, shortens the rehabilitation period. At heart failure improves contractility of a myocardium, increases tolerance to an exercise stress, reduces the frequency of attacks of stenocardia. At acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the ischemia center. It is effective in case of vascular pathology of an eyeground. Drug eliminates functional disturbances of a nervous system at patients with an alcoholism in the period of abstinence.

Pharmacokinetics. The maximum concentration in a blood plasma is reached right after introduction. It is metabolized in an organism with formation of two main metabolites which are removed by kidneys. The elimination half-life makes 3-6 hours.

Indications to use:

As a part of complex therapy of coronary heart disease (stenocardia, a myocardial infarction); chronic heart failure, dishormonal kardimiopatiya;
as a part of complex therapy of an acute disorder of cerebral circulation (an ischemic stroke, cerebrovascular insufficiency);
reduced working capacity; a physical overstrain (including at athletes);
abstinence syndrome at an alcoholism (in a combination with specific therapy);
hemophthalmia and retinal apoplexies of an eye of various etiology, fibrinferments of the central vein of a retina and its branches, retinopathies of various etiology (diabetic, hypertensive).

Route of administration and doses:

Due to a possibility of development of exciting effect drug is recommended to be used in the first half of day.

Cardiovascular diseases

As a part of complex therapy – intravenously on 500 mg – 1,0 g (5-10 ml of solution for intravenous and parabulbar administration of 100 mg/ml), applying all dose at once or having divided it into 2 introductions. A course of treatment – 10-14 days.
Repeated courses (usually 2-3 times a year) – according to the recommendation of the doctor.

Disturbances of cerebral circulation

In an acute phase of disturbance of cerebral circulation enter intravenously 500 mg (5 ml of solution for intravenous and parabulbar administration of 100 mg/ml) 1 time a day within 10 days.

Reduced working capacity, physical overstrain (including at athletes)

At intellectual and exercise stresses (including at athletes) appoint intravenously 500 mg (5 ml of solution for intravenous and parabulbar administration of 100 mg/ml) 1 time a day. A course of treatment - 10-14 days.

Abstinence syndrome at an alcoholism (in a combination with specific therapy)

At an abstinence syndrome apply intravenously 500 mg (5 ml of solution to intravenous and parabulbar administration of 100 mg/ml) 2 times a day. A course of treatment – 10-14 days.

Oftalmopatologiya (hemophthalmia and retinal apoplexies of an eye of various etiology, fibrinferments of the central vein of a retina and its branches, retinopathies of various etiology (diabetic, hypertensive).

The drug is administered parabulbarno on 50 mg (0,5 ml of solution for intravenous and parabulbar administration of 100 mg/ml) within 10 days, including as a part of a combination therapy.

Features of use:

Идринол® is not drug of the first row at an acute coronary syndrome.

Influence on ability to control of motor transport and mechanisms

Data on an adverse effect of the drug Idrinol® on the speed of psychomotor reactions are not available.

Side effects:

From cardiovascular system: seldom - tachycardia, decrease or increase in arterial pressure.
From the central nervous system: seldom - psychomotor excitement.
From the alimentary system: seldom - dispeptic disturbances.
Allergic reactions: seldom – a skin itch, rash, a hyperemia of integuments, a Quincke's disease; very seldom – an eosinophilia.
Others: very seldom - the general weakness.

Interaction with other medicines:

It is possible to combine with anti-anginal means, anticoagulants, antiagregant, antiarrhytmic means, diuretics, bronchial spasmolytics. Strengthens effect of cardiac glycosides.
In view of possible development of moderate tachycardia and arterial hypotension, it is necessary to be careful at a combination with nitroglycerine, nifedipine, alpha adrenoblockers, antihypertensives and peripheral vazodilatator.

Contraindications:

- hypersensitivity to drug components;
- increase in intracranial pressure (at disturbance of venous outflow and intracranial tumors);
- age up to 18 years (efficiency and safety are not established).

With care: diseases of a liver and/or kidneys.

Use at pregnancy and during feeding by a breast

Safety of use of drug at pregnancy is not proved. In order to avoid possible adverse influence on a fruit it is not necessary to appoint drug at pregnancy.

It is unknown whether drug with breast milk is emitted. In need of use of the drug Idrinol® in the period of a lactation breastfeeding should be stopped.

Overdose:

Symptoms: the lowering of arterial pressure which is followed by a headache, tachycardia, dizziness and the general weakness.
Treatment: symptomatic.

Storage conditions:

List B. At a temperature not above 25 °C. Not to freeze. To store in the place, unavailable to children. A period of validity - 3 years. Not to use after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Solution for intravenous and parabulbar administration of 100 mg/ml.
On 5 ml in ampoules of colourless glass.
On 5 ampoules in a blister strip packaging. 1 or 2 blister strip packagings together with the application instruction in a pack from a cardboard.